Andrea I Mcclatchey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5339182/publications.pdf

Version: 2024-02-01

44 papers

7,119 citations

32 h-index 243529 44 g-index

63 all docs 63
docs citations

63 times ranked 8351 citing authors

#	Article	IF	CITATIONS
1	Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature, 1988, 331, 528-530.	13.7	1,105
2	Organizing the cell cortex: the role of ERM proteins. Nature Reviews Molecular Cell Biology, 2010, 11, 276-287.	16.1	884
3	Ezrin Is Essential for Epithelial Organization and Villus Morphogenesis in the Developing Intestine. Developmental Cell, 2004, 6, 855-864.	3.1	373
4	Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. Journal of Cell Biology, 2007, 177, 893-903.	2.3	316
5	The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling. Developmental Cell, 2001, 1, 63-72.	3.1	311
6	Spatial regulation of receptor tyrosine kinases in development and cancer. Nature Reviews Cancer, 2012, 12, 387-400.	12.8	285
7	The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid β-protein gene. Nature, 1987, 329, 156-157.	13.7	275
8	NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes and Development, 2003, 17, 1090-1100.	2.7	263
9	Membrane organization and tumorigenesisthe NF2 tumor suppressor, Merlin. Genes and Development, 2005, 19, 2265-2277.	2.7	238
10	<i>Nf2</i> /Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes and Development, 2010, 24, 1718-1730.	2.7	233
11	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Reports, 2015, 10, 1692-1707.	2.9	213
12	DOCK4, a GTPase Activator, Is Disrupted during Tumorigenesis. Cell, 2003, 112, 673-684.	13.5	211
13	Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship. Science Translational Medicine, 2014, 6, 237ra68.	5.8	203
14	Contact inhibition (of proliferation) redux. Current Opinion in Cell Biology, 2012, 24, 685-694.	2.6	183
15	Merlin and the ERM proteins – regulators of receptor distribution and signaling at the cell cortex. Trends in Cell Biology, 2009, 19, 198-206.	3.6	179
16	Merlin and ERM proteins: unappreciated roles in cancer development?. Nature Reviews Cancer, 2003, 3, 877-883.	12.8	175
17	A Mouse Model Recapitulating Molecular Features of Human Mesothelioma. Cancer Research, 2005, 65, 8090-8095.	0.4	152
18	The NF2 Tumor Suppressor, Merlin, Regulates Epidermal Development through the Establishment ofÂa Junctional Polarity Complex. Developmental Cell, 2010, 19, 727-739.	3.1	145

#	Article	IF	Citations
19	Neurofibromatosis. Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 191-216.	9.6	130
20	Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical and Experimental Metastasis, 2007, 24, 69-78.	1.7	118
21	Regulation of the Neurofibromatosis Type 2 Tumor Suppressor Protein, Merlin, by Adhesion and Growth Arrest Stimuli. Journal of Biological Chemistry, 1998, 273, 7757-7764.	1.6	113
22	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics, Part A, 2012, 158A, 24-41.	0.7	101
23	Ezrin… a metastatic detERMinant?. Cancer Cell, 2004, 5, 113-114.	7.7	97
24	ERM proteins at a glance. Journal of Cell Science, 2014, 127, 3199-204.	1.2	90
25	Localization to the Cortical Cytoskeleton Is Necessary for Nf2/Merlin-Dependent Epidermal Growth Factor Receptor Silencing. Molecular and Cellular Biology, 2008, 28, 1274-1284.	1.1	87
26	Microvilli defects in retinas of ezrin knockout mice. Experimental Eye Research, 2006, 82, 720-729.	1.2	76
27	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clinical Cancer Research, 2009, 15, 5032-5039.	3.2	74
28	Merlin/ERM proteins establish cortical asymmetry and centrosome position. Genes and Development, 2012, 26, 2709-2723.	2.7	60
29	Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9767-9772.	3.3	54
30	NF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin. Journal of Cell Biology, 2015, 211, 391-405.	2.3	54
31	Nf2/Merlin Regulates Hematopoietic Stem Cell Behavior by Altering Microenvironmental Architecture. Cell Stem Cell, 2008, 3, 221-227.	5.2	50
32	Merlin/ERM proteins regulate growth factor-induced macropinocytosis and receptor recycling by organizing the plasma membrane:cytoskeleton interface. Genes and Development, 2018, 32, 1201-1214.	2.7	39
33	Uncovering mutation-specific morphogenic phenotypes and paracrine-mediated vessel dysfunction in a biomimetic vascularized mammary duct platform. Nature Communications, 2020, 11, 3377.	5.8	30
34	Cell–Cell Contact and Receptor Tyrosine Kinase Signaling. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029215.	2.3	23
35	SPRED proteins provide a NF-ty link to Ras suppression. Genes and Development, 2012, 26, 1515-1519.	2.7	16
36	Tumor suppressor mutations in mice: the next generation. Current Opinion in Genetics and Development, 1998, 8, 304-310.	1.5	15

#	Article	lF	CITATIONS
37	Proliferation-independent role of NF2 (merlin) in limiting biliary morphogenesis. Development (Cambridge), $2018, 145, .$	1.2	15
38	Mouse models of neurofibromatosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2001, 1471, M73-M80.	3.3	12
39	EGFR-induced cytoskeletal changes drive complex cell behaviors: The tip of the iceberg. Science Signaling, 2018, 11, .	1.6	12
40	ERM proteins. Current Biology, 2012, 22, R784-R785.	1.8	10
41	Neurofibromatosis type II: mouse models reveal broad roles in tumorigenesis and metastasis. Trends in Molecular Medicine, 2000, 6, 252-253.	2.6	9
42	Actin' Up to Stop SNFin Out TEAD. Developmental Cell, 2018, 47, 693-695.	3.1	3
43	EPHecting cell contact by increasing cortical tension. Journal of Cell Biology, 2021, 220, .	2.3	1
44	Neurofibromatoses., 0,, 253-280.		1